Aurinia Pharmaceuticals Inc. announced that for fiscal year 2022, the Company is providing net revenue guidance of $115 million to $135 million from sales of LUPKYNIS. This range is based on assumptions regarding the impact of COVID-19 on the current business environment and represents an increase of more than 150% to 200% in net revenue from sales of LUPKYNIS compared to fiscal year 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.53 USD | +1.28% |
|
-2.12% | -38.49% |
Jun. 14 | Declaration of Voting Results by Aurinia Pharmaceuticals | CI |
Jun. 14 | Declaration of Voting Results by Aurinia Pharmaceuticals Inc | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-38.49% | 789M | |
+15.19% | 121B | |
+19.91% | 114B | |
+8.24% | 23.61B | |
-19.80% | 20.43B | |
-16.19% | 16.55B | |
-13.45% | 16.45B | |
-44.35% | 15.59B | |
+66.67% | 15.19B | |
+2.13% | 13.54B |
- Stock Market
- Equities
- AUPH Stock
- News Aurinia Pharmaceuticals Inc.
- Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Year 2022